4 randomized controlled trials (n=1833 patients) were included in this meta-analysis for the purpose of comparing analgesic efficacy and safety of tanezumab when compared to placebo treatment. Outcomes of interest included changes in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, WOMAC physical function, patient global assessment, the incidence of adverse events, and treatment discontinuation due to adverse effects. Results demonstrated that patients who were given tanezumab had significantly improved pain, function, and global assessment scores when compared to the placebo group. However, significant increases in therapy discontinuation due to adverse effects, development of abnormal peripheral sensation, and peripheral neuropathy were also observed.